These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10052026)

  • 1. Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension.
    Ahaneku JE; Taylor GO; Agbedana EO
    Int J Clin Pharmacol Res; 1998; 18(4):165-70. PubMed ID: 10052026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension.
    Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
    Int J Clin Pharmacol Res; 1998; 18(4):159-63. PubMed ID: 10052025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
    Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
    J Pak Med Assoc; 1994 Jul; 44(7):166-9. PubMed ID: 7933456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING TREATMENT OF HYPERTENSION WITH CILNIDIPINE.
    Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
    Pharmacol Res; 2000 Jan; 41(1):79-82. PubMed ID: 10712830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING AMLODIPINE TREATMENT OF HYPERTENSION IN JAPANESE PATIENTS.
    Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
    Pharmacol Res; 2000 Jan; 41(1):73-77. PubMed ID: 10712829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.
    Wolfram RM; Brewer HB; Xue Z; Satler LF; Pichard AD; Kent KM; Waksman R
    Am J Cardiol; 2006 Sep; 98(6):711-7. PubMed ID: 16950168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
    Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
    Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of serum lipids and serum lipoprotein spectrum in patients with cerebrovascular diseases.
    Zhou J; Zhang M; Li XM
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Mar; 23(3):262-4. PubMed ID: 12651248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of doxazosin on plasma lipid and lipoprotein levels in hypertensive patients.
    Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
    Pharmacol Res; 1994; 30(3):263-72. PubMed ID: 7862620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased high density lipoprotein cholesterol in adult nephrotic syndrome in Nigeria.
    Adigun MO; Agbedana EO; Kadiri S; Taylor GO
    Afr J Med Med Sci; 1999; 28(1-2):97-100. PubMed ID: 12953996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.